Burkina Faso

190,000

190,000

190,000

200,000

200,000

200,000

200,000

200,000

200,000

200,000

210,000

210,000

210,000

FP2030 Indicator Summary Sheet: 2024 Measurement Report

| Modern Co | ntraceptiv | e Use and | Need | | | | | | Sou | ırce : Family Pla | ınning Estimati | on Tool (FPE |
|---------------------------------------|-----------------------|-----------------|---------------------|---|---|---------------|----------------|---|-----------|-------------------|-----------------|--------------|
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total users of | modern meth | ods of contrace | eption* | l | | l . | | Į. | | Į. | | |
| 650,000 | 730,000 | 810,000 | 870,000 | 950,000 | 1,050,000 | 1,150,000 | 1,210,000 | 1,360,000 | 1,450,000 | 1,530,000 | 1,610,000 | 1,690,00 |
| | | alence rate (mC | | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | , , | , ,,,,,, | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | ,, | ,, | ,,,,,,,, | ,,,,,,, |
| 16.8% | 18.1% | 19.4% | 20.3% | 21.6% | 23.0% | 24.3% | 25.0% | 27.0% | 28.0% | 28.6% | 29.0% | 1 29.5% |
| | | ated to have ar | I. | I. | ļ | I. | ļ | 27.070 | 20.070 | 20.070 | 25.070 | 25.57 |
| Percentage of 20.4% | 20.2% | 20.0% | 19.6% | 18.7% | 17.3% | 16.9% | 16.5% | 16.1% | 15.3% | 14.6% | 14.2% | 13.9% |
| | Į. | ated to have th | I. | I. | ļ | I. | | | 15.5% | 14.0% | 14.270 | 13.970 |
| - | 1 | | 1 | | ı | 1 | | 1 | CA CO/ | 66.40/ | 67.40/ | 67.00 |
| 45.1% | 47.3% | 49.4% | 51.0% | 53.6% | 57.0% | 59.0% | 60.3% | 62.7% | 64.6% | 66.1% | 67.1% | 67.9% |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| | 1 | ods of contrace | 1 | 2010 | 2017 | 2010 | 2013 | 2020 | 2021 | 2022 | 2023 | 2024 |
| 540,000 | 600,000 | 670,000 | i | 800,000 | 990,000 | 060,000 | 1 020 000 | 1 120 000 | 1 210 000 | 1 290 000 | 1 240 000 | 1 400 00 |
| | · · | · | 720,000 | 800,000 | 880,000 | 960,000 | 1,020,000 | 1,130,000 | 1,210,000 | 1,280,000 | 1,340,000 | 1,400,00 |
| | | alence rate (mC | | 22.20/ | 25.50 | 27.00/ | 27.00/ | 22.22 | 24.40/ | 22.20/ | 22.00/ | 22.50 |
| 18.0% | 19.6% | 21.1% | 22.3% | 23.8% | 25.5% | 27.0% | 27.9% | 30.3% | 31.4% | 32.3% | 32.9% | 33.5% |
| | I | ated to have ar | 1 | 1 | I | | ı | I | I | 1 | I | l |
| 24.7% | 24.3% | 23.9% | 23.2% | 22.0% | 20.2% | 19.7% | 19.4% | 19.0% | 18.0% | 17.3% | 16.9% | 16.6% |
| Percentage of | f women estim | ated to have th | eir demand fo | r family planni | ng met with a | modern metho | d of contracep | tion (mDS) | I | ı | I | I |
| 42.2% | 44.7% | 47.1% | 49.0% | 52.0% | 55.7% | 57.8% | 59.0% | 61.6% | 63.5% | 65.0% | 66.1% | 67.0% |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total users of | modern meth | ods of contrace | eption | | | | | | | | | |
| 110,000 | 120,000 | 130,000 | 140,000 | 150,000 | 170,000 | 180,000 | 190,000 | 210,000 | 240,000 | 250,000 | 260,000 | 280,00 |
| Modern conti | raceptive preva | alence rate (mC | CP) | | | , | | , | , | | , | |
| 12.6% | 13.2% | 13.8% | 14.1% | 14.3% | 15.1% | 16.1% | 16.3% | 17.1% | 18.2% | 17.9% | 18.1% | 18.3% |
| Percentage of | women estim | ated to have ar | n unmet need | for modern me | thods of cont | aception (mUN | J) | I | ı | I | ı | |
| 6.2% | 6.8% | 7.4% | 8.0% | 8.3% | 8.3% | 8.3% | 7.9% | 7.5% | 7.5% | 6.7% | 6.7% | 6.6% |
| Percentage of | f women estim | ated to have th | i neir demand fo | r family planni | ng met with a | nodern metho | d of contracep | tion (mDS) | | I | | |
| 66.9% | 66.1% | 65.0% | 63.6% | 63.1% | 64.8% | 65.9% | 67.4% | 69.5% | 71.0% | 72.7% | 72.9% | 73.3% |
| | | | | | | | | | | | ı | |
| mpacts of | Modern C | ontracepti | ive Use an | nong All W | /omen | | | | | | | |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| umber of uninte | 1 | | 1 | ontracentive u | | | | | | | | |
| 250,000 | 270,000 | 300,000 | 330,000 | 360,000 | 400,000 | 430,000 | 460,000 | 510,000 | 550,000 | 580,000 | 610,000 | 640,000 |
| umber of unsaf | 1 ' | | | | 400,000 | 430,000 | 400,000 | 310,000 | 330,000 | 300,000 | 010,000 | 040,00 |
| 89,000 | 99,000 | 110,000 | 118,000 | i . | 143,000 | 156,000 | 165,000 | 194 000 | 107.000 | 200,000 | 210,000 | 220.00 |
| · · · · · · · · · · · · · · · · · · · | | | | 130,000 | 143,000 | 150,000 | 165,000 | 184,000 | 197,000 | 208,000 | 218,000 | 229,00 |
| umber of mater | 1 | 1 | | ì | | | | | 4.000 | | | |
| 480 | 530 | 590 | 640 | 700 | 770 | 840 | 890 | 990 | 1,000 | 1,100 | 1,100 | 1,200 |
| ouple Years of P | Protection (CYP | s) | | | | | | | Co | alculated from | routine service | provision d |
| Source | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
| DHIS2 | | | 905,977 | 1,049,904 | 1,121,976 | 1,263,017 | 1,344,996 | 1,961,897 | 1,284,733 | 1,668,236 | 1,651,875 | 1,755,08 |
| - | | | 222/211 | _,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | _,, | _, | _, , | _,, | _,,, | _, | _, | _,,,,,,,, |
| ertility Ou | tcomes | | | | | | | | | | | |
| • | | | | | | | | | | | | |
| | | | | | | | | | Va | lue | Sou | ırce |
| dolescent birth | rate <i>(per 1000</i> | women 15-19) | | | | | | | ' | | , 300 | |
| | | | | | | | | | 9 | 93 | 2021 | . DHS |
| ercent of births | that are uninte | ended | | | | | | | | | | |
| | | | | | | | | | 1 | 2% | 2021 | . DHS |
| | | | | | | | | | 1 | _, • | | |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| stimated Numb | 1 | | l . | 1 | | 1 | | 1 | ı | 1 | | |
| | | | I | 1 | | I | 1 | I | 1 | 1 | ı | |

Contraceptive Use, Availability, and Discontinuation by Method

| | Modern Contracep | tive Method Mix | |
|-----------------------|------------------------|-----------------|------------|
| Long-Acting | Sterilization (female) | 0.4% | Source |
| and | Sterilization (male) | 0.0% | 2021 DHS |
| Permanent | IUD | 5.4% | |
| Methods | Implant | 46.4% | |
| | Injectable | 23.4% | |
| | Pill | 9.0% | Population |
| | Condom (Male) | 12.9% | All Women |
| Short-Term Methods | Condom (Female) | 0.0% | |
| ivictious | LAM | 1.4% | |
| | Standard Days method | 0.0% | |
| | Other Modern Methods | 1.1% | |

| Long Acting | Sterilization (female) | 4.3% | Source |
|--|-------------------------|-------|------------------|
| Long-Acting and Permanent Methods | Sterilization (male) | 3.9% | UNFPA SDP Survey |
| | IUD | 4.6% | |
| | Implant | 13.0% | |
| | Injectable | 4.5% | |
| | Pill | 7.8% | Year |
| Short-Term | Condom (Male) | 4.5% | 2023 |
| Methods | Condom (Female) | 8.2% | |
| | Emergency Contraception | 24.4% | |
| | Other modern methods | n/a | |

| | Value | Source | Year |
|---|-------|------------------|------|
| Percentage of primary SDPs that have at least 3 modern methods of contraception available on day of | | | |
| | 96% | UNFPA SDP Survey | 2023 |
| Percentage of secondary/tertiary SDPs with at least 5 modern methods of contraception available on | | | |
| | 71% | UNFPA SDP Survey | 2023 |

| Contraceptive Discontinuation Rates and Method Switching (first 12 months)** | | | | | | | | | | |
|--|-------|---------|------------|-------|------------------|----------|--|--|--|--|
| | IUD | Implant | Injectable | Pill | Condom (male) | Source | | | | |
| Discontinuation while in need | 11.2% | 7.3% | 21.7% | 20.3% | 7.6% | | | | | |
| Discontinuation while not in need | 6.0% | 5.9% | 19.2% | 19.4% | 7.5% | 2021 DHS | | | | |
| Total discontinuation (all reasons) | 19.8% | 13.4% | 40.6% | 43.2% | 19.8% | 2021 DH3 | | | | |
| Switching to a different method | 3.2% | 1.4% | 4.0% | 4.4% | 3.2% | | | | | |

Contraceptive Services and Decision-Making

| | Value | Source | Population | | | | | | |
|--|-------|-------------|------------|--|--|--|--|--|--|
| Method Information Index** | | | | | | | | | |
| | 44% | 2024 PMA P4 | All Women | | | | | | |
| Percentage of women who received family planning information during a contact with a health service provider ** | | | | | | | | | |
| | 28% | 2024 PMA P4 | All women | | | | | | |
| Percent of current modern contraceptive users who last obtained their family planning method from each source (All Methods) ** | | | | | | | | | |
| Public | 85% | | | | | | | | |
| Private Medical | 3% | 2021 DHS | | | | | | | |
| Other | 13% | | | | | | | | |
| Percentage of women who decided to use family planning alone or jointly with their husbands/partners ** | | | | | | | | | |
| | 88% | 2024 PMA P4 | | | | | | | |

Investment in Family Planning

| | Value | Year | Source |
|--|-------------|------|--------|
| Annual expenditure on family planning from government domestic budget (USD \$) | | | |
| | \$4,980,769 | 2022 | WHO |

Traditional Contraceptive Use

Source: Family Planning Estimation Tool (FPET)

| traditional Contraceptive ose and not meet the reporting threshold (ice among Marinea Women >5% in 2025) and so is not reported for this country. | | | | | | | | | | | | |
|---|---------------|------|------|------|------|------|------|------|------|------|------|------|
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| All Women | | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Married Women | Married Women | | | | | | | | | | | |
| | | | | | | | | | | | | |
| Unmarried Wome | en | ' | | | | | | | | | | |
| | | | | | | | | | | | | |

Notes

--- indicates no data post 2012 was available

** Additional diaggregation or details available in the full data set.





^{*} Total Users among Married Women and Unmarried Women will not sum exactly to the Total Users among All Women